Evidence map›Paper›PMID 16878047›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2006

Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.

Frank J Palella, Rose K Baker, Anne C Moorman, Joan S Chmiel, Kathleen C Wood, John T Brooks, Scott D Holmberg, HIV Outpatient Study Investigators

3 registry-linked trialsAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 674 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
674citing papers in PubMed, 5 pooled it
28.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01683656 phase4terminatedstarted 2012, after this paper: background citation

ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART

Ran2012Enrolled4Registered outcomes5Posted comparisons0ConditionsAtherosclerosis, HIVArmsNiacin/laropiprant, Placebo
Open the trial in the graph
NCT02453919 recruitingnot on this mapstarted 2010, after this paper: background citation

Register of Cardiovascular Complications Among People Living With HIV

Typeobservational_patient_registrySponsorSaint Antoine University HospitalRan2010 to 2030Enrolled800ConditionsHIV, Cardiovascular Diseases
NCT02898597 nacompletednot on this mapstarted 2016, after this paper: background citation

Smoking Cessation Intervention for Women With HIV/AIDS

TypeinterventionalSponsorUniversity of Massachusetts, BostonRan2016 to 2018Enrolled49ConditionsAIDS/HIVArmsCognitive Behavioral Therapy
3 · Its place in the literature

Who cites it

674 citing papers in PubMed, 5 syntheses or guidelines pooled it, 1,348 citations in OpenAlex.

  1. Pooled it
  2. Examining Depression as a Risk Factor for Cardiovascular Disease in People with HIV: A Systematic Review.Annals of behavioral medicine : a publication of the Society of Behavioral Medicine · 2023
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Statin Therapy Does Not Reduce Liver Fat Scores in Patients Receiving Antiretroviral Therapy for HIV Infection.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2019
    Trial
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Observational
  19. Article
  20. Review

614 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Frank J PalellaDivision of Infectious Diseases, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA. f-palella@northwestern.edu
Rose K Baker
Anne C Moorman
Joan S Chmiel
Kathleen C Wood
John T Brooks
Scott D Holmberg
HIV Outpatient Study Investigators
Centers for Disease Control and Prevention · USCerner (United States) · USGeneral Department of Preventive Medicine · VNNational Center for HIV/AIDS Viral Hepatitis STD and TB Prevention · USOffice of Infectious Diseases · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAIDS-related death and disease rates have declined in the highly active antiretroviral therapy (HAART) era and remain low; however, current causes of death in HAART-treated patients remain ill defined.

objectiveTo describe mortality trends and causes of death among HIV-infected patients in the HAART era.

designProspective, multicenter, observational cohort study of participants in the HIV Outpatient Study who were treated from January 1996 through December 2004. MEASUREMENTS: Rates of death, opportunistic disease, and other non-AIDS-defining illnesses (NADIs) determined to be primary or secondary causes of death.

resultsAmong 6945 HIV-infected patients followed for a median of 39.2 months, death rates fell from 7.0 deaths/100 person-years of observation in 1996 to 1.3 deaths/100 person-years in 2004 (P=0.008 for trend). Deaths that included AIDS-related causes decreased from 3.79/100 person-years in 1996 to 0.32/100 person-years in 2004 (P=0.008). Proportional increases in deaths involving liver disease, bacteremia/sepsis, gastrointestinal disease, non-AIDS malignancies, and renal disease also occurred (P=or<0.001, 0.017, 0.006, <0.001, and 0.037, respectively.) Hepatic disease was the only reported cause of death for which absolute rates increased over time, albeit not significantly, from 0.09/100 person-years in 1996 to 0.16/100 person-years in 2004 (P=0.10). The percentage of deaths due exclusively to NADI rose from 13.1% in 1996 to 42.5% in 2004 (P<0.001 for trend), the most frequent of which were cardiovascular, hepatic, and pulmonary disease, and non-AIDS malignancies in 2004. Mean CD4 cell counts closest to death (n=486 deaths) increased from 59 cells/microL in 1996 to 287 cells/microL in 2004 (P<0.001 for trend). Patients dying of NADI causes were more HAART experienced and initiated HAART at higher CD4 cell counts than those who died with AIDS (34.5% vs 16.8%, respectively, received HAART for 4 of more years, P<0.0001; 22.4% vs 7.8%, respectively, initiated HAART with CD4 cell counts of more than 350 cells/microL, P<0.001).

conclusionsAlthough overall death rates remained low through 2004, the proportion of deaths attributable to non-AIDS diseases increased and prominently included hepatic, cardiovascular, and pulmonary diseases, as well as non-AIDS malignancies. Longer time spent receiving HAART and higher CD4 cell counts at HAART initiation were associated with death from non-AIDS causes. CD4 cell count at time of death increased over time.

Indexed as

AdultAntiretroviral Therapy, Highly ActiveCohort StudiesFemaleHIV InfectionsHumansMaleMiddle AgedOutpatientsPatient SelectionSurvival Analysis

Identifiers

PMID16878047
OpenAlexW1996083965

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.